as well as mentioning CEN yesterday (up today) I also mentioned AKT. This is a good post on this one, thanks to volsung. You asked for a little more info on this one mel:
volsung - 3 Jan'07 - 09:34 - 16159 of 16160
Brian O'connor of the Daily Mail pins his hopes on gene therapy:
For 2007 I am putting my faith in the remarkable technology of gene therapy - manipulation of some of the 30,000 genes in the body to boost your defences or suppress viruses. This area has had setbacks, but the survivors have built a pipeline of potential new drugs at a time when the industry's giants are searching desperately for products.
He doesn't mention OXB prefering Ark but the sentiment is the same.
"Ark Therapeutics is at the forefront. Its pipeline includes Vitor, for weight loss in cancer, and Trinam for kidney patients. Its best prospect is Cerepro, for brain cancer. This could become the first of a new generation of gene-based medicines. Trials suggest a single treatment of Cerepro trebles life expectancy for late stage sufferers.
That only keeps them alive for 12 months, but this might be extended greatly by repeated doses, or adding other treatments.
European drugs regulator EMEA has cleared Ark to produce commercial batches. Full approval could come as early as the first half of 2007. Experts think sales could reach £180m a year or more. At 93¾p Ark is valued at £155m. This month Fidelity bought a 4% stake and took 5.9m warrants. These only pay off if the shares top 140p between 2007 and end-2008 - a remarkable vote of confidence.
Interest in gene research is rising. US giant Merck has just paid £575m for Sirna Therapeutics - more than double its market value. Biotech is risky, but Ark has two years' cash and a highly promising pipeline. Cerepro could transform its prospects - and trigger a bid."
